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Abstract  42 
Several studies suggest that an increase of glutathione (GSH) through activation of the 43 
transcriptional nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in the dopaminergic neurons may 44 
be a promising neuroprotective strategy in Parkinson’s disease (PD). Among Nrf2 activators, 45 
isothiocyanate sulforaphane (SFN), derived from precursor glucosinolate present in Brassica 46 
vegetables, has gained attention as a potential neuroprotective compound. Bioavailability studies 47 
also suggest the contribution of SFN metabolites, including erucin (ERN), to the neuroprotective 48 
effects of SFN. Therefore, we compared the in vitro neuroprotective effects of SFN and ERN at the 49 
same dose level (5 µM) and oxidative treatment with 6-hydroxydopamine (6-OHDA) in SH-SY5Y 50 
cells. The pre-treatment of SH-SY5Y cells with SFN recorded a higher (p<0.05) active nuclear Nrf2 51 
protein (12.0±0.4 vs. 8.0±0.2 fold increase), mRNA Nrf2 (2.0±0.3 vs. 1.4±0.1 fold increase), total 52 
GSH (384.0±9.0 vs. 256.0±8.0 µM) levels and resistance to neuronal apoptosis elicited by 6-OHDA 53 
compared to ERN. By contrast, the simultaneous treatment of SH-SY5Y cells with either SFN or 54 
ERN and 6-OHDA recorded similar neuroprotective effects with both the isothiocyanates (Nrf2 55 
protein 2.2±0.2 vs. 2.1±0.1 and mRNA Nrf2 2.1±0.3 vs. 1.9±0.2 fold increase; total GSH 384.0±4.8 56 
vs. 352.0±6.4 µM). Finally, in vitro finding was confirmed in a 6-OHDA-PD mouse model. The 57 
metabolic oxidation of ERN to SFN could account for their similar neuroprotective effects in vivo, 58 
raising the possibility of using vegetables containing a precursor of ERN for systemic antioxidant 59 
benefits in a similar manner to SFN. 60 
 61 
Keywords: sulforaphane, erucin, 6-hydroxydopamine, Nrf2, Parkinson’s disease. 62 




A considerable amount of evidence supports a role for oxidative stress, mitochondrial dysfunction 65 
and abnormal protein accumulation as early triggers of neuronal death in Parkinson’s disease (PD) 66 
pathogenesis
1,2
. Glutathione (GSH) depletion is one of the earliest altered redox statuses in 67 
substantia nigra (SN) during the progression of PD, probably because of the presence of dopamine 68 
(DA) oxidative metabolism, iron and a weak antioxidant and detoxifying defense system
3,4
. 69 
Based on this evidence, it has been suggested that food-based approaches may be a promising 70 
strategy to prevent or slow the ongoing oxidative stress in PD
5–7
. Recent studies demonstrate the 71 
ability of dietary phytochemicals widely found in fruits and vegetables to reduce the neuronal death 72 
occurring in neurodegenerative diseases through several adaptive mechanisms. These mechanisms 73 
belong to the phenomenon called hormesis, including the activation of the nuclear factor (erythroid-74 
derived 2)-like 2 (Nrf2), a master regulator of the antioxidant network and cytoprotective genes
8–10
. 75 
In this regard, emerging findings also suggest that hormesis involves the activation of multiple 76 
neuroprotective pathways that contribute to restore both mitochondrial dysfunction and abnormal 77 
protein accumulation in PD
11,12
. Among hormetic phytochemicals, the isothiocyanates (ITCs), 78 
derived from precursor glucosinolates, released from eating Brassica vegetables, have gained 79 
attention as potential neuroprotective compounds with the ability to increase total GSH levels and 80 
related enzymes through the activation of Nrf2
13
. In particular, the electrophilic interaction of ITCs 81 
with the cysteine residues of the cytoplasmatic Kelch like-ECH-associated protein 1 (Keap1)-Nrf2 82 
complex is a crucial event to promote the binding of Nrf2 with the antioxidant responsive element 83 
(ARE) at nuclear level
8
. Recent studies show multiple neuroprotective mechanisms of ITC 84 
sulforaphane (4-methyl-sulfinylbutyl ITC, SFN) in several in vitro and in vivo models of acute and 85 
chronic neurodegenerative disease
14,15
. The evidence of neuroprotective effects of SFN at central 86 
nervous system level must take into account the contribution of SFN tissue distribution and 87 
metabolites. SFN is released from precursor glucoraphanin, particularly abundant in watercress, 88 
broccoli and broccoli sprouts, and after the uptake in the organism, is conjugated with GSH and 89 
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metabolized via the mercapturic-acid pathway to its corresponding mercapturic-acid derivate SFN-90 
cysteinylglycine, SFN-cysteine and SFN-N-acetylcysteine
16
. One interesting aspect is the reduction 91 
of the sulfoxide SFN to its thioether analogue erucin (4-methyl-thiobutyl ITC, ERN), which is also 92 
metabolized via the mercapturic-acid pathway and excreted in urine or bile
16
. ERN is also derived 93 
from glucoerucin, a major glucosinolate in Eruca sativa, and shows a similar biotransformation 94 
pathway and excretion fate to SFN (Figure 1). In particular, a biotransformation from ERN to SFN 95 
metabolites has been demonstrated
16
. In recent studies, ERN has shown a potential profile of 96 
antioxidant and neuroprotective effects similar to those observed with SFN. In particular, ERN 97 
increases heme-oxygenase (HO-1) expression and Nrf2 signaling in cultured human colon 98 
carcinoma HT29 cells and in mice, supporting our results that showed how a prolonged pre-99 
treatment of human dopaminergic neuroblastoma SH-SY5Y cells with ERN activated an 100 
antioxidant adaptive response against oxidative damage induced by 6-hydroxydopamine (6-101 
OHDA)
17,18
. Other studies suggest that biological effects elicited by ERN can be considered 102 
separately from those induced by SFN
16
. The determination of SFN and ERN in parallel is therefore 103 
a prerequisite for an adequate interpretation of their biological effects
16
. 104 
To compare the neuroprotective effects of ERN and SFN we determined their neuroprotective 105 
effects, in an in vitro and in vivo 6-OHDA-PD model, at the same dose level and treatment before or 106 
during the oxidant treatment with 6-OHDA. In particular, to mimic the neuronal transient oxidant 107 
events due to the DA in PD, we used an in vitro PD model characterized by a short oxidant 108 
treatment of SH-SY5Y cells with 6-OHDA and subsequent removal of the oxidant treatment to 109 
trigger the impairment of the neuronal redox status and neuronal death. This in vitro experimental 110 
approach allowed us to evaluate: i) the time course of the SFN and ERN adaptive hormetic response 111 
in the absence of oxidant treatment as well as the ability of the adaptive hormetic response recorded 112 
with SFN and ERN to prevent the subsequent oxidative damage elicited by 6-OHDA; ii) the 113 
neuroprotective adaptive response of SFN and ERU that occurs over time by successive short 114 




Materials and Methods 117 
Chemicals 118 
ERN and SFN (both with purity ≥ 98%) were purchased from LKT Laboratories (LKT 119 
Laboratories, St. Paul, MN, USA); 6-OHDA, 7’dichlorodihydrofluorescein diacetate (H2DCF-DA), 120 
anti-β-actin and nrf2 antibodies, apomorphine, monochlorobimane were purchased Sigma-Aldrich 121 
(Sigma-Aldrich, St. Louis, MO, USA). The anti-tyrosine hydroxylase (TH) antibody was purchased 122 
from Millipore (Millipore, Temecula, CA, USA). The Annexin-V-FLUOS Staining Kit, Cell Death 123 
Detection ELISA
PLUS
 kit, aprotinin, leupeptin, and NP-40 were purchased (Roche Diagnostics, 124 
Mannheim, Germany). RNA-to-cDNA Kit, Taqman Universal Master Mix II, and Taqman probe 125 
for Nrf2 gene (ID: Hs00975961_g1) were purchased from Applied Biosystem Inc. (Applied 126 
Biosystem Inc., Foster City, CA, USA). The Nuclear Extract Kit and the TransAM Nrf2 Kit were 127 
purchased from Active Motif (Active Motif, Carlsbad, CA, USA). The goat biotinylated anti-rabbit 128 
IgG antibody and the DAB detection kit were purchased from Vector laboratories (Vector 129 
Laboratories, Burlingame, CA, USA). All reagents were of the highest grade of purity 130 
commercially available.  131 
Cell Culture and Treatments 132 
An SH-SY5Y cell line was routinely grown at 37°C in a humidified incubator with 5% CO2 in 133 
Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 134 
50 U/mL penicillin and 50 μg/mL streptomycin. To evaluate the neuronal redox status, the SH-135 
SY5Y cells were seeded in 96-well plates at 2 x 10
4
 cells/well. To determine neuronal apoptosis 136 
parameters such as membrane phosphatidylserine exposure and DNA fragmentation into 137 
oligosomes, the SH-SY5Y cells were seeded in culture dishes (size 100 mm) at 1.5 x 10
6 
cells/dish 138 
and in 96-well plates at 2.5 x 10
3
 cells/well, respectively. To evaluate active nuclear Nrf2 protein 139 





cells/dish and in 96-well plates at 2 x 10
4
 cells/well, respectively. All experiments were performed 141 
after 24 h of incubation at 37°C in 5% CO2. 142 
To evaluate the ability of SFN and ERN to modulate the neuronal basal levels of active nuclear 143 
Nrf2 protein, total GSH and redox status without treatment with 6-OHDA, SH-SY5Y cells were 144 
treated with 5 μM of ITCs for 1, 3, 6, 12, and 24 h at 37°C in 5% CO2. To determine the 145 
neuroprotective effects of SFN and ERN, SH-SY5Y cells were treated with 5 μM of ITCs 24 h 146 
before or during the treatment with 100 μM of 6-OHDA for 2 h at 37°C in 5% CO2. Next, the 147 
treatment was replaced with a medium without 6-OHDA and ITCs, and after further different 148 
incubation times we evaluated the nuclear active Nrf2 protein level (2 h), total GSH level (16 h), 149 
membrane phosphatidylserine exposure and DNA fragmentation into oligosomes (16 h). 150 
Quantitative Real-Time PCR on Nrf2 gene expression 151 
RNA was extracted from SH-SY5Y cells using the RNeasy mini kit (Qiagen, Hilden, Germany) and 152 
following the manufacturer’s procedures. cDNA was synthesized using the High capacity RNA-to-153 
cDNA Kit. qRT-PCR was carried out using Taqman Universal Master Mix II and the average 154 
mRNA fold change of Nrf2 gene was calculated by comparing the cycle threshold (CT) of the target 155 
gene to that of the housekeeping gene 18-S ribosomal RNA. The Taqman probes span an exon 156 
junction. All reactions had three technical replicates and each condition had three biological 157 
replicates. Relative quantification was calculated with the ΔΔCT method (2
−ΔΔCT
). 158 
Nuclear Extraction and determination of active Nrf2 protein level  159 
Nuclear Extraction and determination of active Nrf2 protein level were performed using the Nuclear 160 
Extract and TransAM Nrf2 Kit, respectively, according to the manufacturer’s guidelines. The 161 
TransAM Nrf2 Kit is a DNA-binding ELISA able to determine the active Nrf2 protein level in 162 
nuclear extract. The primary antibody of the kit is able to recognize an epitope on Nrf2 protein upon 163 
ARE binding. The active Nrf2 protein levels  in the treated cells are expressed as fold increase with 164 
respect to corresponding untreated cells. 165 
Determination of neuronal redox status 166 
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The neuronal redox status in terms of intracellular reactive oxygen species (ROS) levels was 167 
evaluated in SH-SY5Y cells as previously described with minor changes
19
. At the end of the 168 
treatment of SH-SY5Y cells, the culture medium was removed and 100 µL 2’-169 
7’dichlorodihydrofluorescein diacetate, H2DCF-DA, (10 µg/mL) were added to each well. After 30 170 
min of incubation at room temperature, the H2DCF-DA solution was replaced with phosphate buffer 171 
saline and the intracellular ROS levels were measured (excitation at 485 nm and emission at 535 172 
nm) using a multilabel plate reader (VICTOR™ X3). The values are expressed as arbitrary 173 
fluorescence units (AUF). 174 
Determination of membrane phosphatidylserine exposure 175 
Apoptosis in terms of membrane phosphatidylserine exposure was evaluated using the Annexin-V-176 
FLUOS Staining Kit, according to the manufacturer’s instructions. The values are expressed as a 177 
percentage of Annexin-V positive cells. 178 
Animals and experimental design 179 
Male C57Bl/6 mice (9 weeks old, 25-30 g body weight; Harlan, Milan, Italy) were used for the 180 
experiments. All studies were performed in accordance with the Institutional Guidelines and 181 
complied with Italian regulations and associated guidelines of the European Communities Council 182 
Directive (PROT. n. 15-IX/9). The experimental protocol was based on the unilateral stereotaxic 183 
intrastriatal injection of 6-OHDA (AP: + 0.5, ML: – 2.0, DV: – 2.5), as previously described
20
. All 184 
animals tolerated the surgical operations well and there was no mortality due to treatments. Animals 185 
were randomly divided into 4 groups (n=10-12 per group). Three groups received a 6-OHDA 186 
injection in the left striatum, while one group received the same volume of saline solution (sham 187 
group). One hour after brain lesion, we started intraperitoneal (i.p.) administration of either 30 188 
µmol/kg SFN or ERN or vehicle (VH, saline). We injected the mice twice a week. Thus, the four 189 
groups were: Sham/VH; 6-OHDA/VH; 6-OHDA/SFN; 6-OHDA/ERN. Four weeks after the lesion, 190 
we assessed the extent of the lesion using the rotational behavior test. At the end of behavioral 191 
analysis, mice were sacrificed by cervical dislocation to perform neurochemical analysis. 192 
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The SN was rapidly removed from the brain and placed into dry-ice. SN samples were then 193 
homogenized in lysis buffer (50 mM Tris, pH 7.5, 0.4% NP-40, 10% glycerol, 150 mM NaCl, 10 194 
μg/ml aprotinin, 20 μg/ml leupeptin, 10 mM EDTA, 1 mM sodium orthovanadate, 100 mM sodium 195 
fluoride), and protein concentration was determined by the Bradford method.  196 
Rotational behavior 197 
All tests were carried out between 9.30 a.m. and 3.30 p.m. Animals were transferred to the 198 
experimental room at least 1 h before the test in order to let them acclimatize to the test 199 
environment. All scores were assigned by the same observer who was unaware of the animal 200 
treatment. Apomorphine-induced rotations were determined 4 weeks after the surgical procedure, 201 
according to the method described earlier
21
. Briefly, mice received a subcutaneous injection of 202 
apomorphine (0.05 mg/kg saline), a dopamine D1/D2 receptor agonist. They were acclimatized in 203 
plexiglass cylinders for 5 min prior to testing. After apomorphine administration, full body 204 
ipsilateral and contralateral turns were recorded using an overhead videocamera over a period of 10 205 
min. Subsequently, each 360° rotation of the body axes was manually counted as a rotation. Values 206 
were expressed as the mean of contralateral turns collected during 10 min. 207 
Western Blotting 208 
As described
21
, the protein lysates (30 μg per sample) were separated by SDS-polyacrylamyde gels, 209 
and were transferred onto nitrocellulose membranes, which were probed with primary anti-TH and 210 
secondary antibodies. ECL reagents (Pierce, Rockford, IL, USA) were utilized to detect targeted 211 
bands. The same membranes were stripped and reprobed with β-actin antibody. Data were analyzed 212 
by densitometry, using Quantity One software (Bio-Rad). Values are expressed as fold increase 213 
versus respective contralateral intact site. 214 
Immunohistochemistry 215 
Fixed brains were sliced on a vibratome at 40 µm thickness. Sections were deparaffinized and 216 
hydrated through xylene and rinsed in Tris-buffered saline (TBS). After deparaffinization, 217 
endogenous peroxidase was quenched with 3% H2O2. Non-specific adsorption was minimized by 218 
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incubating the section in 10% normal goat serum for 20 min. Sections were then incubated 219 
overnight, at 4°C, with a rabbit anti (TH) or anti-Nrf2 antibody, rinsed in TBS, and re-incubated for 220 
1 h, at room temperature, with a goat biotinylated anti-rabbit IgG antibody. Finally, sections were 221 
processed with the avidin–biotin technique and reaction products were developed using commercial 222 
kits (Vector Laboratories). To verify the binding specificity, some sections were also incubated 223 
with only the primary antibody (no secondary) or with only the secondary antibody (no primary). In 224 
these situations, no positive staining was found in the sections, indicating that the immunoreactions 225 
were positive in all experiments carried out. Image analysis was performed by a blinded 226 
investigator, using an Axio Imager M1 microscope (Carl Zeiss, Oberkochen, Germany) and a 227 
computerized image analysis system (AxioCam MRc5, Zeiss) equipped with dedicated software 228 
(AxioVision Rel 4.8, Zeiss). After defining the boundary of the SN at low magnification (2.5x 229 
objective), the number of TH and Nrf2-positive cells in the SN was counted on – at least – four 230 
adjacent sections at a higher magnification (10x objective). Positive cells were counted and 231 
compared to other experimental groups. 232 
Determination of DNA fragmentation in vitro and in vivo 233 
The determination of DNA fragments into oligosomes was performed using the Cell Death 234 
Detection ELISA
PLUS
 kit according to the manufacturer’s guidelines. In vitro values are expressed 235 
as fold increase with respect to corresponding untreated cells. To determine the in vivo DNA 236 
fragmentation we used lysates corresponding to 80 µg of protein and the values are expressed as the 237 
mean of optical density fold increase with respect to the Sham/VH group. 238 
Determination of total GSH content in vitro and in vivo 239 
Total GSH content in SH-SY5Y cells was determined using the monochlorobimane assay in 96-240 
well plates as previously reported
22
. The values are expressed as concentrations of total GSH (μM) 241 
obtained by a GSH standard curve. Total GSH content in SN samples was estimated as described 242 
previously by us
20
. The values are expressed as mmol GSH/mg of total lysate proteins per assay. 243 
Statistical analysis 244 
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Data are reported as mean ± SEM. Statistical analysis was performed using one-way ANOVA with 245 
Bonferroni post hoc test and Pearson’s correlation coefficient for relations among variables. 246 
Differences were considered significant at p < 0.05. Analyses were performed using PRISM 5 247 
software (GraphPad Software, La Jolla, CA, USA). 248 
Results and Discussion 249 
In vitro neuroprotective effects of SFN and ERN 250 
Initially, we evaluated the ability of SFN and ERN to activate early neuronal adaptive mechanisms 251 
modulating the active nuclear Nrf2 protein, mRNA Nrf2, total GSH levels, and redox status in 252 
terms of intracellular ROS levels without oxidative treatment with 6-OHDA in SH-SY5Y cells. As 253 
reported in Figure 2a, increasing the time of treatment of SH-SY5Y cells with either SFN or ERN 5 254 
μM, a concentration not associated with neurotoxicity (data not shown), showed that the highest 255 
increase of active nuclear Nrf2 protein levels occurred at 1 h. At this time, SFN recorded a 256 
significantly higher fold increase than ERN (12 vs. 8). Less similar patterns of active nuclear Nrf2 257 
protein levels were also determined at 3 and 12 h of treatment. The active nuclear Nrf2 protein 258 
levels recorded at 1 h were also accompanied by a similar compensation response of gene 259 
expression increase of mRNA Nrf2 as shown in Figure 2b. In parallel, comparable treatment times 260 
of SH-SY5Y cells with both the ITCs showed a significant decrease and increase of total GSH and 261 
ROS levels, respectively, (Figure 3a and 3b). Remarkably, SFN recorded significantly greater 262 
effects than ERN on total GSH basal levels at 1 h (percentage decrease, 77 vs. 42) and 6 h 263 
(percentage decrease, 30 vs. 2) as well as on ROS basal levels at 1 h (percentage increase, 30 vs. 264 
12) and 3 h (percentage increase, 15 vs. 0). The highest magnitude of these effects recorded for both 265 
ITCs at 1 h decreased to basal levels when the treatment times of SH-SY5Y cells were extended to 266 
12 h (Figure 3a and 3b). 267 
As shown in Figure 4a and 4b, the higher activation of early adaptive mechanisms, specifically the 268 
increase of active nuclear Nrf2 protein and the total GSH depletion, induced by SFN compared to 269 
ERN was also prodromic in significantly different late adaptive mechanisms, such as increase and 270 
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decrease in total neuronal GSH and ROS levels, respectively, at 24 h of treatment. At this treatment 271 
time, we recorded a significant inverse correlation between ROS and GSH levels for both SFN (r = 272 
–0.76, p <0.01) and ERN (r = –0.93, p <0.001) (Figure 4c). Subsequently, we evaluated the impact 273 
of different total GSH levels recorded after treatment with either SFN or ERN on prevention of 274 
neuronal apoptosis, in terms of membrane phosphatidylserine exposure (Annexin V binding) and 275 
DNA fragmentation into oligosomes elicited by 6-OHDA in SH-SY5Y cells. The pre-treatment of 276 
SH-SY5Y cells for 24 h with either SFN or ERN 5 μM led to a significant decrease of Annexin V 277 
labeled cells induced by 2 h treatment with 6-OHDA and subsequent 16 h treatment without 6-278 
OHDA (Figure 4d). The antiapoptotic effects of SFN were significantly higher than those of ERN, 279 
with a maximum inhibition of 95% and 60% respectively. These effects were confirmed by the 280 
higher ability of SFN to also reduce the DNA fragmentation into oligosomes induced by 6-OHDA 281 
than ERN at 5 μM (Figure 4e). SFN and ERN alone did not change neuronal apoptosis basal levels 282 
(data not shown). 283 
Taken together, these in vitro results show that the higher ability of SFN to prevent the neuronal 284 
death induced by 6-OHDA in SH-SY5Y cells compared to ERN could be ascribed to their different 285 
ability to activate upstream early adaptive mechanisms of GSH synthesis. In this regard, for the first 286 
time we demonstrated the greater ability of SFN to promote the nuclear Nrf2 activation as well as 287 
the increase of GSH than ERN in neuronal SH-SY5Y cells. Interestingly, these findings also 288 
suggest the determining contribution of GSH in maintaining redox balance and neuronal survival. 289 
Recent studies demonstrate that Nrf2 knockdown by siRNA in SH-SY5Y cells abolishes the 290 




The different ability of SFN and ERN to active a neuroprotective adaptive response through nuclear 293 
Nrf2 activation is consistent with the evidence that the SFN containing oxidized sulphur is likely to 294 
be a more potent electrophilic ITC and phase II inducer than analogues containing non-oxidized 295 
sulphur, such as ERN
26,27
. Recent studies show that the electrophilic interaction of SFN with several 296 
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cysteine residues in Keap1, particularly C151, inhibits the Keap1-dependent degradation of Nrf2 297 
and increases the nuclear localization of Nrf2 as well as Nrf2 ARE-binding activity
28,29
. The higher 298 
electrophilicity of SFN than ERN also supports their different ability to induce a transient depletion 299 
of GSH through the intracellular conjugation of SFN and ERN with cellular nucleophiles including 300 
GSH, leading to increased levels of ROS. Other studies recorded similar transient pro-oxidant 301 
effects of SFN and ERN in non-neuronal cells, also suggesting a direct enzymatic redox regulation 302 
of GSH synthesis. In particular, the ROS formation with the depletion of GSH can lead to a 303 
conformational change in the catalytic subunit of gamma-glutamylcysteine synthetase, increasing 304 
its affinity for the substrates gamma-glutamic acid, cysteine, and adenosine triphosphate and 305 
thereby stimulating GSH synthesis
30
. 306 
At present, we do not know the impact of the intracellular metabolism of SFN and ERN on their 307 
different abilities to activate neuronal adaptive mechanisms. In this regard, a recent study recorded 308 
the potential biotransformation of the same dose of SFN to corresponding ERN metabolites at 309 
intracellular levels after 3 h of treatment
16
. However, in view of the early nuclear Nrf2 activation 310 
elicited by both ITCs at 1 h as well as the lower ERN activity recorded we can presume that the 311 
intracellular reduction of SFN does not contribute its highest activity. 312 
In contrast to the experimental approach of pre-treatment, the simultaneous treatment of SH-SY5Y 313 
with either SFN or ERN (5 μM) and 6-OHDA (100 μM) recorded similar neuroprotective effects 314 
with both the ITCs (Figure 5). Interestingly, both SFN and ERN significantly strengthened the 315 
increase of active nuclear Nrf2 protein and total GSH levels elicited by 6-OHDA in SH-SY5Y cells 316 
at 2 h and 16 h, respectively, after co-treatment with 6-OHDA (Figure 5a and 5c). The Nrf2-ARE 317 
binding activation was also matched by a similar profile of compensatory response of mRNA Nrf2 318 
gene expression as shown in Figure 5b. In similar co-treatment conditions, both the ITCs also 319 
showed the ability to counteract the Annexin V labeled cells and the DNA fragmentation into 320 
oligosomes at 16 h (Figure 6a and 6b). 321 
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This experimental approach highlights an adaptive stress response of the antioxidant network, 322 
specifically the GSH system, to oxidative damage of 6-OHDA. When the oxidative damage is too 323 
drastic, these adaptive systems fail, leading to neuronal death
30
. In this context, the neuroprotective 324 
effects of both ITCs could be ascribed to their ability to strengthen the GSH adaptive response at 325 
transcriptional level, ensuring neuronal survival. Interestingly, co-treatment with ERN and 6-326 
OHDA recorded a neuroprotective effect similar to SFN, suggesting an in vitro inter-conversion of 327 
ERN in SFN favored by the oxidative reaction of 6-OHDA.  328 
In vivo neuroprotective effects of SFN and ERN 329 
Four weeks after the lesion, we compared the neuroprotective effects of SFN and ERN against the 330 
oxidative damage induced by 6-OHDA in vivo. In particular, we evaluated the toxicity in 331 
dopaminergic neurons of mice after intrastriatal injection of 6-OHDA and ip administration of 332 
either 30 µmol/kg SFN or ERN. Firstly, we performed a behavioral quantification of dopamine 333 
depletion, by apomorphine-induced rotations 4 weeks after the induced lesion. As reported in 334 
Figure 7, the intrastriatal injection of 6-OHDA significantly increased the number of apomorphine-335 
induced rotations in lesioned mice compared with sham mice (p<0.001, Sham/VH vs 6-336 
OHDA/VH). The protection of functional nigral neurons contributed to the reduction of behavioral 337 
impairments induced by 6-OHDA. Our results demonstrate that SFN and ERN induced a partial 338 
recovery in the rotational behavior test; in fact we still found a difference between the treatment 339 
groups and the sham operated mice. However, statistical analysis of the total net number of 340 
rotations showed that both SFN and ERN treatments counteracted the asymmetric motor behavior 341 
compared to the 6-OHDA/VH group (Fig. 5, p<0.05). These results were confirmed, as reported in 342 
Figure 8a, by the TH levels, a marker for dopaminergic neuronal function, which were significantly 343 
decreased in the SN of 6-OHDA-lesioned mice (85% vs sham/VH), and both SFN and ERN 344 
treatments strongly upregulated the expression of TH (78% and 74% respectively compared to the 345 
6-OHDA/VH group, Figure 8a). To confirm this result, we also performed an immunohistochemical 346 
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analysis on brain coronal slices containing SN structure (Figure 8b-c), and our results showed a 347 
consistent loss in dopaminergic neuronal function (93% vs sham/VH), efficiently counteracted by 348 
our treatments. Similarly, both SFN and ERN treatments protected neuronal tissue from apoptosis 349 
by significantly reducing DNA fragmentation in SN samples induced by intrastriatal injection of 6-350 
OHDA (respectively 54% and 48% compared to the 6-OHDA/VH, Figure 8d). With regard to the 351 
neuroprotective effects of the ITCs, we did not find any significant differences between them 352 
(Figure 8). 353 
As expected, when we measured GSH content it was significantly decreased (Figure 9a) in the 6-354 
OHDA/VH group as compared to the Sham/VH group. More interestingly, SFN and ERN 355 
consistently protected against the 6-OHDA-associated oxidative stress by maintaining GSH close to 356 
baseline values (Figure 9a). Remarkably, we did not record any differences between SFN and ERN 357 
in their ability to restore the GSH levels. 358 
Previous studies in mice have shown the ability of SFN to increase the Nrf2 protein levels in 359 
various brain regions, including basal ganglia, leading to upregulation of phase II antioxidant 360 
enzymes in different stress conditions
31–34
. Among the upregulation of antioxidant molecules and 361 
enzymes by Nrf2, we demonstrated the contribution of the increased GSH levels in striatum to the 362 
neuroprotective effects of SFN found in 6-OHDA-PD mouse model
20
. 363 
To confirm that the neuroprotective effects of SFN and ERN recorded against 6-OHDA are the 364 
consequence of the same upstream redox adaptive mechanisms, we also performed an 365 
immunostaining for Nrf2-positive cells on brain coronal slices containing SN structure (Figure 9b-366 
c). As we expected, four weeks after the lesion was induced it was possible to observe a consistent 367 
loss in Nrf2 activity (45% vs Sham/VH group), efficiently restored by the treatment with SFN or 368 
ERN, but we did not find any difference between these ITCs in the inductive response. 369 
Interestingly, in the oxidative stress conditions the restoration of Nrf2 induced by both ITCs 370 
significantly exceeded basal levels of the Sham/VH group, also suggesting the activation of long 371 
16 
 
term adaptive effects. It is plausible that in addition to direct short-time term adaptive effects on the 372 
GSH system elicited by 6-OHDA oxidative stress, the ITC treatment for four weeks strengthened 373 
the long term adaptive effects in SN at transcriptional, epigenetic and genomic level
30
. 374 
Taken together, these results demonstrate for the first time that in the presence of ongoing oxidative 375 
damage processes ERN can exert similar in vivo neuroprotective effects to SFN. These finding are 376 
also supported by our in vitro results that recorded higher neuroprotective effects of SFN than ERN 377 
when we treated the neuronal cells with both ITCs before, but not during, the oxidative stress 378 
induced by 6-OHDA. Therefore, we can presume that the oxidation state of the sulphur in the side 379 
chain of ERN affects its ability to activate early prodromal adaptive mechanisms of neuroprotective 380 
effects. 381 
Systemic metabolism may also play an important part in determining the neuroprotective activity of 382 
ERN in vivo. Several studies of bioavailability and biotransformation show that the sulphur of ERN 383 
is extensively oxidized in mice, rats and humans, forming SFN, while SFN is partly reduced to 384 
ERN
35–37
. In particular, the systemic metabolic inter-conversion of these ITCs would also account 385 
for their similar inductive antioxidant action in vivo (phase II enzyme activities)
26,38–40
. However, 386 
this interpretation is speculative considering the limitation of our study, such as the lack of 387 
determination of SFN and ERN levels in mouse biological fluids. Although various studies 388 
recorded the ITC inter-conversion in similar mouse animal species, the contribution of this 389 
metabolic inter-conversion from ERN to SFN at brain level remains to be clarified
16,35,40
. A recent 390 
study in mice in the absence of oxidative stress conditions reported the ability of glucoerucin, a 391 
glucosinolate precursor of ERN, to induce the expression of the HO-1 gene upregulated by Nrf2 in 392 
the intestinal mucosae and liver but not in the brain, reinforcing the hypothesis that the oxidative 393 
stress could play a more important role than the neuronal metabolism for the oxidation of ERN to 394 





Regarding the neuroprotective mechanisms of SFN and ERN, the in vitro experimental approach 396 
also allowed us to define the neuroprotective time window of dietary ITCs on PD initiation and 397 
progression. The higher neuroprotective effects of SFN than ERN recorded with a long treatment of 398 
neurons before the oxidative damage suggest that a chronic exposure to dietary SFN could reduce 399 
the risk of developing PD in healthy subjects. Instead, the similar neuroprotective effects obtained 400 
after a short combined treatment with SFN or ERN and 6-OHDA indicate the potential ability of 401 
both dietary SFN and ERN to slow the neuronal transient oxidant events due to the DA in subjects 402 
with ongoing PD. In this regard, the effective relationship between the 5 μM concentration of SFN 403 
and ERN used in our in vitro experiments and that occurring in humans is a concern. By contrast 404 
with other individual phytochemicals, the effective concentrations of ITCs in vitro are more likely 405 
to occur in vivo
10
. Our in vitro concentration level is routinely used in neuroprotection studies with 406 
SFN and very similar to the 2.2 and 7.4 µM concentrations of SFN in the human plasma after 407 
consumption of standard broccoli and high-glucosinolate broccoli, respectively
41
. In this regard, a 408 
more recent study in mouse model also detected comparable concentrations of total ITC metabolites 409 
in plasma (1-2 µM) as well as the conversion of ERN to SFN metabolites after isothiocyanate ERN 410 
oral gavage
40
. Overall, our findings and considerations support the development of vegetable 411 
products containing precursors of SFN and/or ERN for nutritional interventions aimed at preventing 412 
or delaying the progression of PD. 413 
 414 
Abbreviations used 415 
6-OHDA     6-hydroxydopamine 416 
ARE            Antioxidant Responsive Element 417 
AUF            Arbitrary Fluorescence Units 418 
ERN            4-methyl-thiobutyl isothiocyanate (Erucin) 419 
DA              Dopamine  420 
GSH            Glutathione 421 
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HO-1           Heme Oxygenase 1 422 
H2DCF-DA 7’dichlorodihydrofluorescein diacetate  423 
H2O2                 Hydrogen Peroxide 424 
Keap-1         Kelch like-ECH-associated protein 1 425 
ip                  Intraperitoneal  426 
ITCs             Isothiocyanates 427 
Nrf2             Nuclear Factor (Erythroid-derived 2)-like 2 428 
PD                Parkinson’s Disease 429 
ROS             Reactive Oxygen Species 430 
SFN             4-methyl-sulfinylbutyl isothiocyanate (Sulforaphane) 431 
SN               Substantia Nigra 432 
TH               Tyrosine Hydroxylase 433 
TBS             Tris-Buffered Saline 434 
VH              Vehicle 435 
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Figure captions 583 
Figure 1. Chemical structure of (a) SFN and (b) ERN. 584 
Figure 2. Effects of SFN and ERN on neuronal basal levels of active nuclear Nrf2 protein and 585 
mRNA Nrf2 in SH-SY5Y cells. (a) SH-SY5Y cells were treated for different lengths of time with 5 586 
μM of either SFN or ERN in the absence of treatment with 6-OHDA. At the end of the treatment, 587 
active nuclear Nrf2 protein levels were measured as described in the Materials and Methods section. 588 
The nuclear Nrf2 protein values are expressed as fold increase with respect to untreated cells. 589 
Values are shown as mean ± SEM (n=4-6). 
*
p < 0.05. 
**
p < 0.01 and 
***
p < 0.001 vs. untreated cells; 590 
§
p < 0.05 and 
§§
p < 0.01 vs. cells treated with ERN; at ANOVA with Bonferroni post hoc test. (b) 591 
At the end of the 1 h treatment, Nrf2 mRNA relative expression was evaluated as described in the 592 
Materials and Methods section. The values were calculated through the 2
-ΔΔCt
 method and expressed 593 
as fold increase with respect to untreated cells. Values are presented as mean ± SEM (n=4-6). 
§
p < 594 
0.05 vs. cells treated with ERN; at ANOVA with Bonferroni post hoc test. 595 
Figure 3. Effects of SFN and ERN on neuronal basal levels of total GSH and ROS in SH-596 
SY5Y cells. (a-b) SH-SY5Y cells were treated for different lengths of time with 5 μM of either 597 
SFN or ERN in the absence of treatment with 6-OHDA. At the end of the treatment, total GSH 598 
and ROS levels were measured as described in the Materials and Methods section. Total GSH 599 
values are expressed as concentrations of total GSH (µM) obtained by a GSH standard curve. 600 
The ROS values are expressed as arbitrary fluorescence units (AUF). Values are shown as 601 
mean ± SEM (n=4-6). 
*
p < 0.05, 
**
p < 0.01 and 
***
p < 0.001 vs. untreated cells; 
§
p < 0.05, vs. 602 
cells treated with ERN; at ANOVA with Bonferroni post hoc test. 603 
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Figure 4. SFN and ERN improve neuronal redox status and prevent neuronal apoptosis induced 604 
by 6-OHDA in SH-SY5Y cells. (a-b) SH-SY5Y cells were treated for 24 h with 5 μM of either 605 
SFN or ERN in the absence of treatment with 6-OHDA. At the end of treatment, total GSH and 606 
ROS levels were measured as described in the Materials and Methods section. Total GSH 607 
values are expressed as concentrations of total GSH (µM) obtained by a GSH standard curve. 608 
ROS values are expressed as arbitrary fluorescence units (AUF). Values are shown as mean ± 609 
SEM (n=4-6). 
*
p < 0.05 and 
**
p < 0.01 vs. untreated cells; 
§
p < 0.05 vs. cells treated with ERN; 610 
at ANOVA with Bonferroni post hoc test. (c) Correlation between total GSH and ROS levels 611 
recorded after 24 h of treatment with 5 μM of either SFN or ERN. (d-e) SH-SY5Y cells were 612 
treated for 24 h with 5 μM of either SFN or ERN and then with 6-OHDA (100 μM) for 2 h. 613 
Next, the treatment was replaced with a medium without 6-OHDA and ITCs, and after a further 614 
16 h incubation we determined the neuronal apoptosis, in terms of membrane 615 
phosphatidylserine exposure (Annexin V binding) and DNA fragmentation into oligosomes, as 616 
described in the Materials and Methods section. Values are expressed as percentage of Annexin 617 
V labeled neurons and fold increase of DNA fragmentation with respect to untreated cells. 618 
Values are shown as mean ± SEM (n=4-6). 
*
p < 0.05, 
**
p < 0.01 and 
***
p < 0.001 vs. cells 619 
treated with 6-OHDA; 
§
p < 0.05 vs. cells treated with 6-OHDA/ERN; 
§§§
p < 0.001 vs. untreated 620 
cells; at ANOVA with Bonferroni post hoc test. 621 
Figure 5. SFN and ERN strengthen Nrf2 and total GSH adaptive stress response elicited by 6-622 
OHDA. (a-b) SH-SY5Y cells were treated with 6-OHDA (100 μM) and either SFN or ERN (5 623 
μM) for 2 h. Next, the treatment was replaced with a medium without 6-OHDA and ITCs, and 624 
after a further 2 h incubation we determined the active nuclear Nrf2 protein levels and Nrf2 625 
mRNA relative expression as described in the Materials and Methods section. Values are 626 
expressed as fold increase with respect to untreated cells. Values are shown as mean ± SEM 627 
(n=4). 
*
p < 0.05 and 
**
p < 0.01 vs. untreated cells; 
§
p < 0.05 and 
§§
p < 0.01 vs. cells treated with 628 
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6-OHDA; at ANOVA with Bonferroni post hoc test. (c) SH-SY5Y cells were treated with 6-629 
OHDA (100 μM) and either SFN or ERN (5 μM) for 2 h. Next, the treatment was replaced with 630 
a medium without 6-OHDA and ITCs, and after a further 16 h incubation we determined the 631 
total GSH levels as described in the Materials and Methods section. Values are expressed as 632 
fold increase with respect to untreated cells. Values are shown as mean ± SEM (n=4). 
*
p < 0.05 633 
and 
***
p < 0.001 vs. untreated cells; 
§§
p < 0.01 vs. cells treated with 6-OHDA; at ANOVA with 634 
Bonferroni post hoc test. 635 
Figure 6. SFN and ERN counteract neuronal apoptosis induced by 6-OHDA in SH-SY5Y 636 
cells. (a-b) SH-SY5Y cells were treated with 6-OHDA (100 μM) and either SFN or ERN (5 637 
μM) for 2 h. Next, the treatment was replaced with a medium without 6-OHDA and ITCs, and 638 
after a further 16 h incubation we determined the neuronal apoptosis, in terms of membrane 639 
phosphatidylserine exposure (Annexin V binding) and DNA fragmentation into oligosomes, as 640 
described in the Materials and Methods section. Values are expressed as a percentage of 641 
Annexin V labeled neurons and fold increase of DNA fragmentation with respect untreated 642 
cells. Values are shown as mean ± SEM (n=4). 
§§
p < 0.01 and 
§§§
p < 0.001 vs. cells treated with 643 
6-OHDA; at ANOVA with Bonferroni post hoc test. 644 
Figure 7. SFN and ERN ameliorate the performance on apomorphine-induced rotational 645 
behavior in 6-OHDA-lesioned mice. C57Bl/6 mice were treated ip (30 µmol/kg) with either 646 
SFN or ERN twice a week for four weeks after intrastriatal injection of 6-OHDA. The number 647 
of net ipsi and contralateral rotations was counted for 10 min. Values are expressed as mean ± 648 
SEM (n=10) of contralateral turns collected during 10 min. 
***
p<0.001 vs. Sham/VH, 
§
p<0.05 649 
vs. 6-OHDA/VH; at ANOVA with Bonferroni post hoc test. 650 
Figure 8. SFN and ERN counteract neuronal death and DNA fragmentation in 6-OHDA lesioned 651 
mice. (a-c) After 4 weeks of treatment with ITCs (30 µmol/kg), TH protein levels were detected by 652 
27 
 
(a) Western Blotting and (b-c) immunohistochemistry in brain coronal sections containing SN. (a) 653 
Top: representative images of protein expression; Bottom: quantitative analysis of the Western 654 
Blotting results for the TH protein levels in SN samples. Values were normalized to -actin and 655 
expressed as mean of fold increase ± SEM (n=10) of each group compared to the intact control site. 656 
(b) Representative photomicrographs of immunostaining on lesioned side, scale bar 100 µm; (c) 657 
histogram representing dopaminergic cell survival in the SN. Values are expressed as mean ± SEM 658 
(n=10) of the percentage of surviving TH-positive cells of the lesioned hemisphere compared to the 659 
intact hemisphere. 
***
p < 0.001 vs. Sham/VH; 
§§§ 
p < 0.01 vs. 6-OHDA/VH; at ANOVA Bonferroni 660 
post hoc test. (d) DNA fragmentation was determined in SN samples as described in the Materials 661 
and Methods section. Values are expressed as mean of fold increase ± SEM (n=10). 
*
p < 0.05 vs. 662 
Sham/VH; 
§§
p < 0.01 and 
§§§
p < 0.001 vs. 6-OHDA/VH; at ANOVA with Bonferroni post hoc test. 663 
Figure 9. SFN and ERN increase total GSH and Nrf2 levels in 6-OHDA lesioned mice. After 4 664 
weeks of treatment with ITCs (30 µmol/kg), (a) total GSH and (b-c) Nrf2 levels were measured in 665 
SN samples as described in the Materials and Methods section. (a) Total GSH values are expressed 666 
as the mean of total GSH (mmol)/mg protein obtained by a GSH standard curve. Values are shown 667 
as mean ± SEM (n=10). (b) Representative photomicrographs of immunostaining for Nrf2 in brain 668 
coronal sections containing the SN, scale bar 100 µm; (c) Quantitative analysis of the number of 669 
positive cells to Nrf2 activation. Values are expressed as mean ± SEM (n=10) of positive cells in 670 
each experimental group. 
*
p < 0.05, 
**
p < 0.01 and 
***
p < 0.001 vs. Sham/VH; 
§
p < 0.05, 
§§
p < 0.01 671 
and 
§§§
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